4 October 2017
(Oxford, UK and Conshohocken, US, 4 October 2017) Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces the appointment of Andrew Hotchkiss as Chief Commercial Officer (CCO).
Andrew joins Immunocore from Eli Lilly & Co, where he held a number of global leadership positions across multiple therapeutic areas and geographies including as Vice President International Business Unit Leader Oncology and President Biomedicines Business Units, Australia, Canada and Europe.
Andrew will be based at Immunocore’s headquarters in Oxford, UK and, as CCO, will oversee Immunocore’s global commercial operations and the preparation of the implementation of the Company’s future commercial strategy.
Eliot Forster, Chief Executive Officer at Immunocore, said: “We are delighted to welcome Andrew to Immunocore where he will be instrumental in preparing the Company for its first potential product launch with IMCgp100, and ultimately the commercialisation of other assets as they move through clinical development. The combination of Andrew’s vast international commercial knowledge and extensive global leadership experience at Lilly is invaluable and will complement our outstanding leadership team.”
Andrew Hotchkiss commented: “Immunocore is a truly unique company, whose TCR technology sets it apart from the crowd and underpins its aspiration to change medical practice in the most challenging disease areas. The opportunity to work closely with such a dynamic and passionate team in a company with the potential to have such a radical impact on medical practice in areas from cancer to infectious disease was too good to turn down. I look forward to playing a part in the Immunocore story.”
Please click on the link below to download the full Press Release: